tiprankstipranks
Baillie Gifford Acquires 4.99% Stake in Genmab A/S
Company Announcements

Baillie Gifford Acquires 4.99% Stake in Genmab A/S

Genmab (GMAB) has released an update.

Pick the best stocks and maximize your portfolio:

Genmab A/S, a leading biotechnology firm, announced that Baillie Gifford & Co now holds 4.99% of its shares, signaling a significant investment by the major shareholder. The company, renowned for its innovative antibody therapeutics and ambitious vision to revolutionize treatment for cancer and other serious diseases by 2030, emphasizes its strong international presence and a 25-year legacy of technological advancements in the biotech industry.

For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyGenmab upgraded to Market Perform from Underperform at Bernstein
TheFlyGenmab announces results from ongoing clinical trials of epcoritamab
TheFlyGenmab announces new results from Phase 1b/2 EPCORE NHL-2 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App